UY30391A1 - HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND - Google Patents

HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND

Info

Publication number
UY30391A1
UY30391A1 UY30391A UY30391A UY30391A1 UY 30391 A1 UY30391 A1 UY 30391A1 UY 30391 A UY30391 A UY 30391A UY 30391 A UY30391 A UY 30391A UY 30391 A1 UY30391 A1 UY 30391A1
Authority
UY
Uruguay
Prior art keywords
hepatitis
aciclic
oxym
compound
protease inhibitors
Prior art date
Application number
UY30391A
Other languages
Spanish (es)
Inventor
Zhe Wang
Ying Sun
Yat Sun Or
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of UY30391A1 publication Critical patent/UY30391A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de formula I o sus sales aceptables para uso farmacéutico, ésteres, o prodrogas: que inhiben la actividad de la serina proteasa, particularmente la actividad de la proteasa del virus de la hepatitis C (HCV) NS3-NS4A. En consecuencia, interfieren con el ciclo de vida del virus de la hepatitis C y también son utiles como agentes antivirales. Composiciones farmacéuticas que comprenden los compuestos mencionados para su administracion a un sujeto que sufra de una infeccion por HCV. Métodos para tratar una infeccion por HCV en un sujeto administrando una composicion farmacéutica que comprende los compuestos de la presente invencion.Compounds of formula I or their salts acceptable for pharmaceutical use, esters, or prodrugs: which inhibit the activity of serine protease, particularly hepatitis C virus (HCV) NS3-NS4A protease activity. Consequently, they interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Pharmaceutical compositions comprising the compounds mentioned for administration to a subject suffering from an HCV infection. Methods for treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

UY30391A 2006-06-06 2007-06-06 HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND UY30391A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81146406P 2006-06-06 2006-06-06
US50338506A 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
UY30391A1 true UY30391A1 (en) 2008-01-31

Family

ID=38832101

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30391A UY30391A1 (en) 2006-06-06 2007-06-06 HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND

Country Status (5)

Country Link
AR (1) AR063942A1 (en)
CL (1) CL2007001630A1 (en)
TW (1) TW200815481A (en)
UY (1) UY30391A1 (en)
WO (1) WO2007146695A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
CA2709089A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis c serine protease inhibitors
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
CN104640572B (en) 2012-05-15 2018-04-27 索伦托医疗有限公司 Drug conjugates, coupling method, and application thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
CN114685453A (en) 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 Heterocyclic prolinamide derivatives
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CN110904121B (en) * 2019-12-17 2022-11-29 南京农业大学 Application of susceptibility gene SR30 in improving crop resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
AR063942A1 (en) 2009-03-04
CL2007001630A1 (en) 2008-02-08
TW200815481A (en) 2008-04-01
WO2007146695A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
DOP2019000218A (en) INHIBITORS OF MACROCYCLIC PROLINES DERIVED HCV SERINE PROTEASES
UY30527A1 (en) TETRAZOLILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
UY30392A1 (en) HEPATITIS C PROTEASE INHIBITING MACROCICLIC OXIMYL COMPOUNDS
ECSP077649A (en) PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
UY30391A1 (en) HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND
UY30437A1 (en) QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C
ECSP10010254A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
CO6571891A2 (en) Hepatitis C virus inhibitors
CO2020002980A2 (en) Antiviral agents against hepatitis b.
UY28423A1 (en) INHIBITORS OF SERINE PROTEASES, IN SPECIAL PROTEASA NS3-NS4A OF HCV.-
MX2010010276A (en) Fluorinated macrocyclic compounds as hepatitis c virus inhibitors.
ECSP088258A (en) SERINA PROTEASAS INHIBITORS
MX2010006210A (en) Fluorinated tripeptide hcv serine protease inhibitors.
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
MX2010006209A (en) Quinoxalinyl derivatives.
MX2011012155A (en) Macrocyclic compounds as hepatitis c virus inhibitors.
MX2010008109A (en) Difluorinated tripeptides as hcv serine protease inhibitors.
MX2010008108A (en) Heteroaryl-containing tripeptide hcv serine protease inhibitors.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170627